Drug(s) - Companies

There are 14 RRMS Brand Name, 2 RRMS Generic Name and 2 SPMS Brand Name FDA-Approved Disease-Modifying Agents. Plus 1 walking drug (non-disease-modifying).
For injectable medication, it is advised to get refresher training once per year. Avoid injecting in tattoos, birthmarks, scar tissue and skin irregularities. Always check with a doctor before starting or stopping medications.
ORAL Walking
Medication
Ampyra by: Biogen Idec, approved in 2013.
(Twice a day pill)
"is the only prescription medicine indicated to help improve walking in adults with MS" **This is NOT a disease modifying drug**
https://ampyra.com/
ORAL
Medication
Aubagio -by: Sanofi Genzyme, approved in 2012.
(A once a day oral pill)
"Is approved by FDA to treat relapsing forms of MS."
www.aubagio.com/
Gilenya by: Norvartis, approved in 2010.
(A once a day oral pill)
"Is a prescription medication use to treat relapsing forms of MS."

www.gilenya.com/index.jsp
For kids 10-17 years old
www.gilenya.com/multiple-sclerosis/treatment-results-children

****FDA SAFETY ALERT****
11/20/18
"Gilenya (fingolimod): Drug Safety Communication - Severe Worsening of Multiple Sclerosis After Stopping the Medicine"

Find groups at:
www.fda.gov/Drugs/DrugSafety/ucm626095.htm
Mavenclad by: EMD Serono, approved in 2019
(oral medication that is given in only two annual courses for a maximum of 20 days over a period of two years. No additional treatments are needed for the next two years)
"is used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults."
www.mavenclad.com/en/now-approved
Mayzent by: Norvartis, approved in 2019.
(Patient receive a starter pack of tablets that gradually increases the daily dose over 5 days)
"is the first treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS) in over 15 years[1]" and relapsing MS.
Ponvory by: Janssen approved in 2021
(A daily oral pill)
"approved by the FDA for the treatment of people with relapsing forms of MS"
www.janssen.com/janssen-announces-us-fda-approval-ponvory-ponesimod-oral-treatment-adults-relapsing-multiple
Tecfidera by: Biogen Idec, approved in 2013.
(A daily oral pill)
"approved by the FDA for the treatment of people with relapsing forms of MS"
www.tecfidera.com/
Vumerity by: Biogen, approved in 2019.
(Twice a day pill)
"is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults"
www.vumerity.com/en_us/home.html
Zeposia by: Bristol Myers approved in 2020.
(A once a day oral pill)
The FDA approved ozanimod, which will carry the brand name Zeposia, for the treatment of relapsing MS.
www.zeposia.com/multiple-sclerosis/

www.zeposia.com/
INJECTABLEMedication
Avonex -by: Avonex,approved in 1996.
(A
once a week injection-intramuscular)
"Is approved by FDA to treat relapsing forms of MS."
https://www.avonex.com/


Betaseron by: Bayer, approved in 1993.
(A every other day injection-
subcutaneously)
"Is indicated for patients with clinically isolated syndrome (CIS) and have MRI features consistent with MS as well as Relapsing-Remitting MS."
www.betaseron.com
Copaxone by: Teva, approved in 1996.
(*40mg three day per week injection-
subcutaneously. *20mg A daily injection-subcutaneously)
"Is indicated for the reduction of the frequency of relapses in relapsing-remitting MS, including patients who have experienced a first clinical episode and have MRI features consistent with MS."
www.copaxone.com/
Extavia by: Norvartis, approved in 2009.
(A every other day injection-subcutaneously)
"Is a prescription medication approved for the treatment of relapsing forms of MS."
www.extavia.com
Glatiramer Acetate by: Mylan, approved in 2018.
(40 mg three times per week injection subcutaneously)
"indicated for the treatment of patients with relapsing-forms of multiple sclerosis. generic equivalent of Copaxone" *Generic Drug*
www.glatirameracetate.com/
Glatopa by: Sandoz, approved in 2015.
(20mg daily and 40 three times per week injection-subcutaneously)
"is indicated for the treatment of patients with relapsing-forms of multiple sclerosis. generic equivalent of Copaxone 20mg dose" *Generic Drug*
http://glatopa.com/
Plegridy by: Biogen Idec, approved in 2014.
(A bi-weekly injection-subcutaneously)
"Is approved by FDA to treat the long-term treatment of relapsing forms of MS."
www.plegridy.com/
Rebif  by: EMD Serono, approved in 2002.
(A three day per week injection-
subcutaneously)
"Is a prescription medication use to treat relapsing forms of MS."
www.rebif.com
INFUSION (IV)Medication
Lemtrada by: Genzyme, approved in 2014.
(First Treatment: 12 mg/day on 5 consecutive days (60 mg total dose). Second Treatment: 12 mg/day on 3 consecutive days (36 mg total dose) administered 12months after the first treatment course.)
"is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile,and should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS."
 
Novantrone by: Suboxone, approved in 2002.
(A
infusion (IV) therapy)
"An immunosuppressant that is approved for use in patients with worsening RRMS, AND is the only approved disease modifying drug for secondary-progressive MS, or progressive-relapsing MS."
www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/treatments/medications/mitoxantrone/index.aspx
Ocrevus by: Genentech, approved in 2017
(A infusion (IV) therapy)
"
is a prescription medicine used to treat adults with relapsing or primary progressive forms of multiple sclerosis"
https://ocrevusevents.com/
Tysabri by: Biogen Idec, approved in 2006.
(A infusion (IV) therapy given once every four weeks)
"Is a prescription medication approved for adult patients with relapsing forms of MS."
www.tysabri.com